Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2023

  1. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study

    Microorganisms, Vol. 11, Núm. 11

2022

  1. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2021

  1. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey

    Neurology and Therapy, Vol. 10, Núm. 2, pp. 833-845

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2020

  1. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    Journal of Clinical Oncology, Vol. 38, Núm. 32, pp. 3753-3762

2019

  1. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

2018

  1. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials

    Alzheimer's and Dementia, Vol. 14, Núm. 6, pp. 837-842

  2. MRI predictors of amyloid pathology: Results from the EMIF-AD Multimodal Biomarker Discovery study

    Alzheimer's Research and Therapy, Vol. 10, Núm. 1

2017

  1. Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in spain

    ClinicoEconomics and Outcomes Research, Vol. 9, pp. 39-47

  2. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study

    Vaccine, Vol. 35, Núm. 39, pp. 5264-5270

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2011

  1. Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: Better pain relief, sleep and physical health

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 656-663

2010

  1. Assessing physician attitudes and perceptions of Alzheimer's disease across Europe

    Journal of Nutrition, Health and Aging, Vol. 14, Núm. 7, pp. 537-544

2007

  1. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    Lancet, Vol. 369, Núm. 9561, pp. 559-570

2006

  1. Lack of localization of 5-HT6 receptors on cholinergic neurons: Implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release

    European Journal of Neuroscience, Vol. 24, Núm. 5, pp. 1299-1306

2004

  1. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer

    New England Journal of Medicine, Vol. 350, Núm. 11, pp. 1081-1092

  2. About the guidelines for outpatient parenteral antimicrobial therapy [1] (multiple letters)

    Clinical Infectious Diseases

  3. De-escalation therapy in ventilator-associated pneumonia

    Critical Care Medicine, Vol. 32, Núm. 11, pp. 2183-2190